M&A Deal Summary

Lodo Therapeutics Acquires Hibiskus BioPharma

On September 3, 2020, Lodo Therapeutics acquired life science company Hibiskus BioPharma

Acquisition Highlights
  • This is Lodo Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Lodo Therapeutics’ 2nd transaction in the United States.
  • This is Lodo Therapeutics’ 1st transaction in Michigan.

M&A Deal Summary
Date 2020-09-03
Target Hibiskus BioPharma
Sector Life Science
Buyer(s) Lodo Therapeutics
Deal Type Add-on Acquisition

Target

Hibiskus BioPharma

Kalamazoo, Michigan, United States
Hibiskus BioPharma, Inc. is an early-stage pharmaceutical venture pursuing the development of a novel small-molecule cancer therapy, TIR-199. Hibiskus BioPharma is based in Kalamazoo, Michigan.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lodo Therapeutics

New York, New York, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Lodo Therapeutics Corp. is a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously undruggable disease targets. Lodo Therapeutics was established in 2015 and is based in New York City.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Michigan) 1 of 1
Country (United States) 2 of 2
Year (2020) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-07 Conifer Point Consulting

Doylestown, Pennsylvania, United States

Conifer Point Pharmaceuticals LLC provides drug discovery researchers create successful drug candidates by combining experimental and computational techniques to design and improve early stage compounds. Conifer Point Pharmaceuticals was established in 2014 and is based in Doylestown, Pennsylvania.

Buy -
Mergr

Product

Company

Legal